Cancer
Mouse studies suggest inhibiting CXCR2 could help treat pancreatic ductal adenocarcinoma (PDAC). In a mouse model of PDAC, CXCR2 knockout decreased tumor growth and the number of tumor-infiltrating neutrophils and increased survival and the ratio of effector T cells to suppressor T cells in the tumor microenvironment compared with normal CXCR2 expression. Next steps could include testing CXCR2 antagonists in PDAC models.
Ligand Pharmaceuticals Inc. and Merck & Co. Inc. have navarixin (MK-7123; SCH 527123), a CXCR2 antagonist, in Phase II testing for chronic obstructive pulmonary disease (COPD)...
BCIQ Company Profiles
BCIQ Target Profiles